The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Bristol-Myers Squibb has new data backing up the value of mavacamten for obstructive hypertrophic cardiomyopathy (HCM), as it waits for a delayed verdict on its marketing application for the drug ...

The CTLA4 inhibitor – now given the brand name Imjudo – is only the second drug in the class to be approved after Bristol-Myers Squibb's well ... review time for the application to six months.

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target ...

An FDA advisory panel on Bristol Myers Squibb Opdivo and Merck Keytruda will examine if PD-L1 tumor expression should limit ...

Bristol Myers Squibb Co. closed $10.05 below its 52-week high ($59.46), which the company reached on September 22nd.

Shares of Bristol Myers Squibb Co. BMY slipped 1.45% to $49.02 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713 ...

The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program.  | Bristol Myers ...

Bristol Myers Squibb announces Phase 3 DAYBREAK trial data showing Zeposia (ozanimod) reduces brain volume loss in relapsing multiple sclerosis patients.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...